Coffee and Ready-to-Drink Coffee in the U.S., 7th Edition

Coffee and Ready-to-Drink Coffee in the U.S., 7th Edition

This comprehensive Packaged Facts report examines both the foodservice spectrum for java-including coffeehouse chains like Starbucks and Caribou Coffee, quick-service restaurants like McDonald’s and Dunkin’ Donuts, convenience store chains, and office coffee service-and the retail market for packaged ground, whole bean, single-serve (e.g., K-Cups, T-Discs, pods), instant, and ready-to-drink (RTD) coffee. The Market Overview chapter covers market trends and opportunities with projections through 2016. Among the trends affecting this market are: the impact of the recession and economic recovery; worldwide green coffee prices; opportunities to market coffee to Hispanic consumers; and health and wellness benefits. Global market perspective is also provided.

Request a Sample for or Inquire before buying the report @
http://www.reportsnreports.com/reports/143437-coffee-and-ready-to-drink-coffee-in-the-us-7th-edition.html

The report includes market sizing for both the foodservice and retail universes, while quantifying retail mass-market sales at the marketer/brand share level using data from SymphonyIRI. It also thoroughly maps out the competitive situation, with detailed profiles of trend-making marketers and foodservice providers including Caribou Coffee, Dunkin’ Donuts, Green Mountain Coffee Roasters, Kraft Foods, McDonald’s, Nestlé, Peet’s Coffee & Tea, Sara Lee, J.M. Smucker, Starbucks, and others.

An extensive analysis of consumer behavior is based on exclusive primary data from Packaged Facts’ September 2011 Online Consumer Survey, and Experian Simmons’ 2011 national consumer panel data to gauge consumer attitudes and purchasing patterns, brand preferences, demographics, and media usage both traditional and social. A thorough review of product launches draws on new product data from Datamonitor’s Product Launch Analytics database, and includes dozens of images of new products and consumer advertising and marketing promotions.
Major points covered in Table of Contentsof this report include:
OVERVIEW
EXECUTIVE SUMMARY
MARKET DEFINITION
MARKET OVERVIEW AND CONTEXT
PRODUCT FORECASTS: BIOLOGICS
PRODUCT FORECASTS: SMALL MOLECULES (TOPICAL)
PRODUCT FORECASTS: SMALL MOLECULES (ORAL)
BIBLIOGRAPHY

Explore Comprehensive list of more than 595 Tables & Figures available in the report Coffee and Ready-to-Drink Coffee in the U.S., 7th Edition

Market and Product Forecasts: Psoriasis – Novel products and current biologics to fuel future market growth

Market and Product Forecasts: Psoriasis – Novel products and current biologics to fuel future market growth

Owing to delayed competition from key contender Ozespa (briakinumab; Abbott), a favorable dosing regimen, and expansion into Japan in March 2011, Stelara will continue its ascendance in the seven major psoriasis markets (the US, Japan, France, Germany, Italy, Spain and the UK), reaching peak sales of $1,516m by 2016.
AIN457 (secukinumab; Novartis) could be the first-to-market interleukin (IL)-17 drug for psoriasis. Akin to IL brand Stelara’s superb performance to date, Datamonitor forecasts high uptake for AIN457, with sales of $252m by 2020, following launch in 2014. Making AIN457 a key growth driver of the systemic anti-psoriasis class over the next decade.
Ozespa’s future in psoriasis remains unclear, after its US and EU regulatory filings were withdrawn in January 2011, owing to safety issues. Datamonitor projects commercial success hinged on Abbott resubmitting US and EU regulatory applications. With estimated launch by 2013, its sales are forecast to reach $308m by 2020.

Request a Sample for or Inquire before buying the report @
http://www.reportsnreports.com/reports/143444-market-and-product-forecasts-psoriasis-novel-products-and-current-biologics-to-fuel-future-market-growth.html

Features and benefits :
Access Datamonitor’s patient based psoriasis market forecast of over 50 products in the seven major markets, with clear methodology and assumptions.
Assess current and future patient-numbers and enhance understanding of the impact future events may have on these.
Evaluate which novel products Datamonitor expects to launch over the coming decade, and how each of these will alter the market.
Gain insight into the psoriasis competitive landscape, and determine which brands drive growth.

Major points covered in Table of Contentsof this report include:
OVERVIEW
EXECUTIVE SUMMARY
MARKET DEFINITION
MARKET OVERVIEW AND CONTEXT
PRODUCT FORECASTS: BIOLOGICS
PRODUCT FORECASTS: SMALL MOLECULES (TOPICAL)
PRODUCT FORECASTS: SMALL MOLECULES (ORAL)
BIBLIOGRAPHY

Explore Comprehensive list of more than 114 Tables & Figures available in the report Market and Product Forecasts: Psoriasis – Novel products and current biologics to fuel future market growth

Market and Product Forecasts: Multiple Sclerosis - New drugs to radically change treatment algorithm and grow market

Market and Product Forecasts: Multiple Sclerosis – New drugs to radically change treatment algorithm and grow market

The seven major multiple sclerosis markets is expected to show slight value growth from 2011 to 2020 at a CAGR of 1.7% to generate $10.0 billion at the end of this period. This growth will be driven by drugs offering improved efficacy and a less invasive method of administration than current treatments.

By 2020, the US will remain the biggest marketplace for multiple sclerosis drug developers at $6.9bn. The UK and Japan are set to remain the smallest of the seven major markets at $111m and $200 in 2020. High hurdles, such as NICE, have restricted market access and availability in the UK.

With a convenient mode of administration and improved efficacy, sales of Novartis’s Gilenya and Biogen’s BG-12 are expected to overtake older brands and become the highest-selling multiple sclerosis drugs with seven major market sales of $2.2bn and $1.2bn, respectively, in 2020.

Request a Sample for or Inquire before buying the report @
http://www.reportsnreports.com/reports/143436-market-and-product-forecasts-multiple-sclerosis-new-drugs-to-radically-change-treatment-algorithm-and-grow-market.html

Features and benefits

• Access Datamonitor’s patient-based multiple sclerosis market forecast, with transparent methodologies and assumptions across the seven major markets.
• Evaluate sales value and volume forecasts to 2020 at the country, class, product, and indication level for disease modifying and symptomatic therapies
• Understand how market drivers and resistors will shape the future market dynamics.
• Quantify the impact of new products launches by understanding Datamonitor’s assumptions on launch dates, pricing, and penetration rates.

Explore Comprehensive list of more than Tables & Figures available in the report Market and Product Forecasts: Multiple Sclerosis – New drugs to radically change treatment algorithm and grow market

Home Care in Portugal

Home Care in Portugal
Development of new products reinforce position of leading player:
Unilever Jerónimo Martins Lda, the leading player of home care, was able to gain more ground in 2010. The launch of its Surf brand in automatic detergents and the extension of its Cif brand to hand dishwashing in 2009 allowed the company to retain its position and to counter private label growth. This was the only branded manufacturer able to reinforce its competitive position against private label, which overall ranked second, continuing to benefit from the unfavourable economic context and higher consumer price-sensitivity. Private label’s success was also linked with the increasing perception consumers have about getting good value-for- money.

Home care purchases continue to be made in supermarkets/hypermarkets:
For their weekly or monthly purchases of home care, consumers continued to prefer grocery retailers, in particular supermarkets/hypermarkets that offered a large choice of products and prices. Due to their lower disposable incomes, consumers reduced their visits to retailers where prices were less attractive, such as small grocery retailers or convenience stores. They were also increasingly attracted by shopping on the internet, as this distribution channel offers a wide range of products and prices and allows consumers to purchasing without leaving home.

Request a Sample for or Inquire before buying the report @ 
http://www.reportsnreports.com/reports/142833-home-care-in-portugal.html

Modest positive performance expected over forecast period:
Home care is predicted to register modest constant value growth over the forecast period. Due to the maturity of a high number of categories, volume decrease is expected. In addition, the growing popularity of economy brands and promotional activities that will be increasingly used by manufacturers to boost sales will inhibit stronger overall value performance. Nevertheless, there are still some categories, such as automatic dishwashing tablets, liquid detergents and electric air fresheners, with high growth potential. Driven by growing concerns about the environment, the “green” segment offers good growth prospects over the forecast period. For their part, branded manufacturers are expected to continue to endorse new products by existing well-known brands in order to reduce their financial investments but also ensure rapid success in categories or segments with attractive growth potential.

Major points covered in Table of Contentsof this report include

EXECUTIVE SUMMARY

KEY TRENDS AND DEVELOPMENTS

MARKET INDICATORS

MARKET DATA

DEFINITIONS

Home Care in Portugal – Company Profiles

3M Portugal Lda in Home Care (Portugal)

F Lima SA in Home Care (Portugal)

Manulena Lda in Home Care (Portugal)

Explore Comprehensive list of more than 203 Tables & Figures available in the report Home Care in Portugal.

Tissue and Hygiene in Bulgaria

Tissue and Hygiene in Bulgaria

Tissue and hygiene sales recover following the crisis:

Although sales of tissue and hygiene products declined in 2009 as a result of the economic crisis, in 2010 the market managed to recover slightly and recorded growth of 1% in current value terms as consumers shifted towards products with higher prices, particularly in retail tissue, where current value growth was even higher.

Sales of premium products decline as a result of the crisis:

After the main effects of the crisis were felt in Bulgaria in 2009 many consumers had to reconsider their spending and traded down to cheaper products. Consequently, the share of cheaper tissue and hygiene products, for example lower-ply formats and private label, increased noticeably. At the same time, consumers in larger cities and which shop in modern retail chains were attracted by the advertising and promotional campaigns of companies such as Ficosota Syntez OOD and Palomita AD, which are positioned in the mid-priced segment. As a result, products in the premium segment suffered a decline in sales while those in the mid-priced and economy segments grew.

Request a Sample for or Inquire before buying the report @ 

http://www.reportsnreports.com/reports/142550-tissue-and-hygiene-in-bulgaria.html

Local producers strengthening their positions:

Domestic producers of tissue and hygiene products in Bulgaria managed to strengthen their positions during the course of 2010. The leading local company, ZH Belovo AD, continued to lead the market. However, its leadership is being seriously challenged by rival players such as SCA Hygiene Holding AB, Palomita AD and Ficosota Syntez OOD. However, all of these are local companies, with multinationals commanding weaker positions.

Major points covered in Table of Contentsof this report include

EXECUTIVE SUMMARY

KEY TRENDS AND DEVELOPMENTS

MARKET INDICATORS

MARKET DATA

DEFINITIONS

Tissue and Hygiene in Bulgaria – Company Profiles

Astera AD in Tissue and Hygiene (Bulgaria)

Axxon Bulgaria OOD in Tissue and Hygiene (Bulgaria)

Medica AD in Tissue and Hygiene (Bulgaria)

Palomita AD in Tissue and Hygiene (Bulgaria)

ZH Belovo AD in Tissue and Hygiene (Bulgaria)

Away-From-Home Tissue and Hygiene in Bulgaria – Category Analysis

Explore Comprehensive list of more than 179 Tables & Figures available in the report Tissue and Hygiene in Bulgaria.